T T Yee
Overview
Explore the profile of T T Yee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
359
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peyvandi F, Mamaev A, Wang J, Stasyshyn O, Timofeeva M, Curry N, et al.
J Thromb Haemost
. 2018 Oct;
17(1):52-62.
PMID: 30362288
Essentials Recombinant von Willebrand factor (rVWF) is effective in von Willebrand disease (VWD). A phase 3 study of rVWF, with/without recombinant factor VIII (rFVIII) before surgery in VWD. Overall rVWF's...
2.
Yee T, Amrolia P, Lee C, Mir N, Giangrande P
Haemophilia
. 2016 May;
3(3):220-1.
PMID: 27214812
No abstract available.
3.
The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease
Makris M, Federici A, Mannucci P, Bolton-Maggs P, Yee T, Abshire T, et al.
Haemophilia
. 2014 Nov;
21(3):338-342.
PMID: 25381842
Recurrent gastrointestinal bleeding is one of the most challenging complications encountered in the management of patients with von Willebrand disease (VWD). The commonest cause is angiodysplasia, but often no cause...
4.
Anderson J, Brewer A, Creagh D, Hook S, Mainwaring J, McKernan A, et al.
Br Dent J
. 2013 Nov;
215(10):497-504.
PMID: 24264665
Recommendations for dental preventive strategies and treatment planning were originally developed through consensus meetings by the Scottish Oral Health Group for Medically Compromised Patients and published in 2003 as a...
5.
Watson H, Wilde J, Dolan G, Millar C, Yee T, Makris M
Haemophilia
. 2013 Apr;
19(3):e191-2.
PMID: 23600911
No abstract available.
6.
Negrier C, Lienhart A, Numerof R, Stephens D, Wong W, Baghaei F, et al.
Haemophilia
. 2013 Jan;
19(3):e143-50.
PMID: 23282031
Factor VIII Inhibitor Bypassing Activity (FEIBA) can effectively achieve haemostasis in haemophilia patients with inhibitors. Further evaluation of FEIBA in surgical settings is of significant interest considering the relatively limited...
7.
Rangarajan S, Austin S, Goddard N, Negrier C, Rodriguez-Merchan E, Stephensen D, et al.
Haemophilia
. 2012 Sep;
19(2):294-303.
PMID: 22989234
A growing number of publications have described the efficacy and safety of FEIBA as a first-line haemostatic agent for surgical procedures in haemophilia A patients with high-responding FVIII inhibitors. The...
8.
Mahlangu J, Coetzee M, Laffan M, Windyga J, Yee T, Schroeder J, et al.
J Thromb Haemost
. 2012 Feb;
10(5):773-80.
PMID: 22353395
Background: BAY 86-6150 is a new human recombinant factor VIIa variant developed for high procoagulant activity and longer action in people with hemophilia with inhibitors. Objectives: To investigate the safety,...
9.
Sorensen B, Benson G, Bladen M, Classey S, Keeling D, McLaughlin P, et al.
Haemophilia
. 2011 Dec;
18(4):598-606.
PMID: 22151135
Treatment studies in haemophilia focus on joint bleeds; however, some 10-25% of bleeds occur in muscles. This review addresses management of muscle haematoma in severe haemophilia, defines gaps in the...
10.
Wilde J, Mutimer D, Dolan G, Millar C, Watson H, Yee T, et al.
Haemophilia
. 2011 Jun;
17(5):e877-83.
PMID: 21658165
Chronic HCV infection continues to be of significant clinical importance in patients with hereditary bleeding disorders. This guideline provides information on the recent advances in the investigation and treatment of...